FDA quickly approves J&J's Darzalex in multiple myeloma

Johnson & Johnson’s Darzalex has acquired another indication after the FDA quickly approved it as part of a combination in newly-diagnosed multiple myeloma patients who are transplant i

Denmark's Genmab prepares for $500m US IPO

Antibody-based drugs firm Genmab, noted for developing the blood cancer drug Darzalex with Johnson & Johnson’s Janssen unit, is preparing for a $500 million US IPO.

AZ's Imfinzi on target in small cell lung cancer, sets up Ro...

AstraZeneca’s Imfinzi cancer immunotherapy has hit the mark in a phase 3 trial in extensive-stage small cell lung cancer, setting up a potential rivalry with Roche’s PD-L1 class drug Tecent

Gilead joins protein degradation drive with Nurix deal

NHS England to prioritise 'tumour agnostic' cancer drugs

NHS England is to prioritise cancer drugs that target tumours according to their genetic makeup rather than where they originate in the body, the organisation’s chief executive has said.

Daiichi waits on FDA as AML drug quizartinib approved in Jap...

The Japanese regulator has approved Daiichi Sankyo’s quizartinib for certain patients with acute myeloid leukaemia (AML), amid doubts over the outcome of a regulatory review in the US.